The Covid-19 vaccine race appears to be entering the home stretch. For biotech investors, the trouble could be just beginning.
Despite a recent pullback, biotech investors are pricing in multiple Covid-19 vaccine breakthroughs in the near future. Pfizer and its partner BioNTech could have late-stage clinical data as soon as the end of October, while data from Moderna is expected soon after. Johnson & Johnson and Novavax have also recently begun their own late-stage trials and could have data within a few months.
Real Life. Real News. Real Voices
Help us tell more of the stories that matterBecome a founding member
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe